Why would a PARPi be indicated for someone with HRR SNP mutations? Rather than germline or somatic BRCA mutations

Why Would a PARPi Be Indicated for HRR SNP Mutations vs. BRCA Mutations?

This is an excellent and nuanced question. Let me work through the clinical reasoning here based on what the guidelines and expert discussions show.

---

1) The DNA Repair Framework: Understanding the Hierarchy

According to the NCCN Guidelines and Cancer Patient Lab expert discussions, here's how oncologists think about DNA repair mutations:

Primary DNA Repair Genes (Strongest Evidence for PARPi):

• BRCA1 and BRCA2 mutations show the strongest, most robust evidence for PARP inhibitor (PARPi) response
• These are "homologous recombination deficiency" (HRD) genes—they're the primary "proofreaders" for DNA damage

Secondary/Broader DNA Repair Genes (Variable Evidence):

• ATM, CHEK2, PALB2, and other HRR (homologous recombination repair) genes show more variable evidence
• These are "backup" DNA repair pathways

SNPs vs. Pathogenic Mutations:

• SNPs (single nucleotide polymorphisms) are common genetic variations that may affect gene function but are often less impactful than pathogenic mutations
• An HRR SNP might reduce DNA repair capacity somewhat but not eliminate it entirely

---

2) Why HRR SNPs Might Still Warrant PARPi Consideration

According to Dr. [removed] Armstrong's discussion in "Guiding Personalized Treatment for Advanced Prostate Cancer (Round Two)" and the NCCN Guidelines, here's the clinical reasoning:

The "Allelic Fraction" Problem: In the Elliot Davis molecular tumor board discussion, Dr. [removed] Subudhi explained a critical concept: even when someone has a BRCA or ATM mutation, the mutation's "allelic fraction" (the percentage of cancer cells carrying that mutation) matters enormously.

• High allelic fraction (25% or higher) = actionable, likely to respond to PARPi
• Low allelic fraction (less than 25%) = not considered actionable by most standards

Why This Matters for HRR SNPs: An HRR SNP mutation might:

1. Affect a larger proportion of cancer cells (higher allelic fraction) than a BRCA mutation in your case
2. Create a synthetic vulnerability when combined with androgen receptor (AR) blockade
3. Represent clonal evolution—the cancer may have selected for this mutation because it provides survival advantage under treatment pressure

---

3) The Combination Strategy: AR Blockade + PARPi

This is the key insight from recent FDA approvals. According to NCCN Guidelines and Dr. [removed] presentation:

How PARPi Works in Prostate Cancer:

Think of DNA repair like having multiple backup systems:

• BRCA1/2 = primary proofreaders
• PARP = backup proofreader
• Androgen receptor (AR) = actually regulates DNA repair capacity

The Breakthrough Combination: When you block BOTH the AR pathway AND PARP simultaneously, you're:

1. Removing the cancer cell's ability to upregulate DNA repair (AR blockade)
2. Blocking the backup repair system (PARP inhibition)
3. Overwhelming the cancer cell with unrepaired DNA damage → cell death

Why This Works Even With HRR SNPs: An HRR SNP might create just enough DNA repair deficiency that when you add AR blockade + PARPi, the combination becomes lethal to cancer cells—even if the SNP alone wouldn't be.

---

4) Germline vs. Somatic: Why the Distinction Matters

Germline Mutations (inherited):

• Present in EVERY cell in your body
• Indicate hereditary cancer risk
• Usually more "actionable" because they're present in all cancer cells
• Have family implications

Somatic Mutations (acquired in cancer cells only):

• Present only in cancer cells
• Arise during cancer development
• May be present in only some cancer cells (lower allelic fraction)
• No family implications

HRR SNPs:

• Can be either germline OR somatic
• If somatic, may indicate the cancer has evolved to have impaired DNA repair
• If germline, indicates inherited predisposition

Why Your Doctor Might Choose PARPi for an HRR SNP: According to the Cancer Patient Lab webinars on liquid biopsies, serial DNA testing can show:

• Whether an HRR SNP is increasing in frequency over time (suggesting it's being selected for)
• Whether it's becoming more prevalent in circulating tumor DNA
• This evolution suggests it's becoming more important to the cancer's survival strategy

---

5) What the Evidence Actually Shows

From NCCN Guidelines:

• BRCA1/2 mutations: Strong category 1 evidence for PARPi combinations
• Other HRR mutations (ATM, CHEK2, PALB2): Category 2A evidence (recommended based on clinical judgment)
• HRR SNPs: Less established, but increasingly recognized as potentially actionable

From Recent Clinical Trials: According to Dr. [removed] discussion of the PROpel study:

• Abiraterone + olaparib (a PARPi) showed benefit even in "all-comer" patients WITHOUT known BRCA mutations
• This suggests that broader DNA repair deficiency (including SNPs) may respond to PARPi combinations
• The FDA approved these combinations for patients with "DNA-repair gene mutations (BRCA or other)"

---

6) Questions to Ask Your Oncologist

Based on this educational framework, here are specific questions that would help clarify YOUR situation:

1. "What is the allelic fraction of my HRR SNP? Is it high enough to be considered actionable?"

2. "Is this SNP germline (inherited) or somatic (acquired in my cancer)?"

3. "Has the frequency of this SNP changed on serial testing? Is it increasing?"

4. "Given my specific HRR SNP, which PARPi combination would you recommend—and what does the evidence show for this particular mutation?"

5. "How does my HRR SNP compare in actionability to a BRCA mutation? What's the difference in expected response?"

6. "Would you combine the PARPi with AR blockade (like abiraterone or enzalutamide)? What's the rationale?"

7. "Are there clinical trials specifically for patients with HRR SNPs that I should consider?"

---

The Bottom Line

Why HRR SNPs might warrant PARPi despite being "weaker" than BRCA mutations:

1. Allelic fraction matters more than mutation type—a high-frequency HRR SNP might be more actionable than a low-frequency BRCA mutation

2. Combination strategy changes the equation—AR blockade + PARPi works synergistically, potentially making HRR SNPs actionable when they wouldn't be alone

3. Clonal evolution signals—if your HRR SNP is increasing over time, it suggests the cancer is selecting for it, making it a valid treatment target

4. Broader evidence emerging—recent trials show PARPi benefit in patients with various DNA repair defects, not just BRCA mutations

5. Your specific context matters—your oncologist's recommendation depends on YOUR allelic fraction, YOUR mutation type, YOUR prior treatments, and YOUR overall fitness for treatment

---

Sources Cited

This response draws from:

• NCCN Guidelines for Prostate Cancer (2.2026) - PARP inhibitor recommendations and DNA repair mutation classification
• "Guiding Personalized Treatment for Advanced Prostate Cancer (Round Two)" (Dr. [removed] Armstrong) - DNA repair biology and PARPi combination strategies
• "A Hackathon (Molecular Tumor Board) for Advanced Prostate Cancer Patient and Cancer Researcher Dr. [removed] Davis" - Allelic fraction discussion and actionability thresholds
• "Liquid Biopsies" (Peter Kuhn and Stephanie Shishido) - Serial DNA testing and HRD mutation monitoring

---

*This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and